Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in brain tumours.

Rakesh K Jain1, Emmanuelle di Tomaso, Dan G Duda

  • 1Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA. jain@steele.mgh.harvard.edu

Nature Reviews. Neuroscience
|July 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No Evidence for Depletion of Circulating Lymphocyte Populations in Primary Brain Tumor Patients Receiving Radiation Therapy Alone.

International journal of radiation oncology, biology, physics·2026
Same author

Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression.

Research square·2026
Same author

Immortalized smooth muscle cells enhance in vitro vasculogenesis.

Research square·2026
Same author

Immortalized smooth muscle cells enhance in vitro vasculogenesis.

bioRxiv : the preprint server for biology·2026
Same author

Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer.

Cancer letters·2026
Same author

Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Malignant gliomas are fatal despite treatment. Anti-vascular endothelial growth factor (VEGF) therapies may normalize tumor blood vessels, creating opportunities for combined treatments against glioblastoma.

Area of Science:

  • Neuro-oncology
  • Cancer biology
  • Vascular biology

Background:

  • Malignant gliomas, including glioblastoma, have a poor prognosis despite multimodal therapy.
  • Tumor angiogenesis, driven by vascular endothelial growth factor (VEGF), promotes an aggressive tumor microenvironment.
  • Abnormal tumor vasculature contributes to hypoxia and high interstitial fluid pressure, selecting for more malignant cells.

Purpose of the Study:

  • To review the role of VEGF in glioblastoma progression.
  • To evaluate the potential of anti-VEGF therapies in glioblastoma treatment.
  • To explore the therapeutic window created by anti-VEGF agents for combination therapies.

Main Methods:

  • Review of preclinical and clinical data on anti-VEGF therapies in glioblastoma.

Related Experiment Videos

  • Analysis of the impact of anti-VEGF agents on tumor vasculature.
  • Assessment of the potential for combining anti-VEGF therapy with chemotherapy and radiation.

    • Main Results:

    • Emerging data suggest anti-VEGF therapies show potential efficacy in glioblastoma.
    • Anti-VEGF treatment can transiently normalize aberrant tumor vasculature.
    • Vessel normalization may improve the delivery and efficacy of chemotherapeutics and radiation.

    Conclusions:

    • Anti-VEGF therapy represents a promising strategy for glioblastoma.
    • Transient normalization of tumor vasculature by anti-VEGF agents creates a therapeutic window.
    • Optimizing combination strategies involving anti-VEGF therapy, chemotherapy, and radiation is crucial for improving glioblastoma outcomes.